Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking

Feb 13 2018

• By Joseph Haas

Prescription Opiate and Heroin Abuse

Related Content

Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol

Dec 02 2017

J&J Wins Nucynta ER Approval, Targets Chronic Pain Market

Aug 26 2011

Pfizer to settle Celebrex and Bextra suits for $894 million

Oct 20 2008

Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab

Feb 08 2018

Purdue Is Open For Business Deals And Shopping On Multiple Fronts

Feb 01 2017

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

May 09 2017

Related Companies

Purdue Pharma L.P.

Eli Lilly and Company

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Additional Topics

Research & Development Financing Commercial Drug Safety Neurology BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window